Patents by Inventor Adrian Ochsenbein

Adrian Ochsenbein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD70 COMBINATION THERAPY
    Publication number: 20240033353
    Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
    Type: Application
    Filed: June 14, 2023
    Publication date: February 1, 2024
    Inventors: Johannes DE HAARD, Samson FUNG, Nicolas LEUPIN, Adrian OCHSENBEIN, Carsten RIETHER, Luc VAN ROMPAEY
  • CD70 combination therapy
    Patent number: 11712468
    Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: August 1, 2023
    Assignees: ARGENX BV, University of Bern
    Inventors: Johannes De Haard, Samson Fung, Nicolas Leupin, Adrian Ochsenbein, Carsten Riether, Luc Van Rompaey
  • Anti-CD70 and BCR-ABL inhibitor combination therapy
    Patent number: 11571475
    Abstract: Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: February 7, 2023
    Assignee: University of Bern
    Inventors: Carsten Riether, Christian Schürch, Adrian Ochsenbein, Karen Silence
  • LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
    Publication number: 20210253723
    Abstract: The present invention relates to a non-agonist ligand, particularly an antibody, that specifically binds to LIGHT or its receptor LT?R thereby interrupting the interaction of LIGHT with LT?R for use in treatment of a haematologic malignancy.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 19, 2021
    Applicant: UNIVERSITÄT BERN
    Inventors: Adrian OCHSENBEIN, Sabine HÖPPNER, Carsten RIETHER
  • CD70 COMBINATION THERAPY
    Publication number: 20200222532
    Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 16, 2020
    Inventors: Johannes DE HAARD, Samson FUNG, Nicolas LEUPIN, Adrian OCHSENBEIN, Carsten RIETHER, Luc VAN ROMPAEY
  • Anti-CD70 combination therapy
    Patent number: 10391168
    Abstract: Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 27, 2019
    Assignee: UNIVERSITY OF BERN
    Inventors: Carsten Riether, Christian Schürch, Adrian Ochsenbein, Karen Silence
  • TREATMENT FOR ACUTE MYELOID LEUKEMIA
    Publication number: 20190106498
    Abstract: Methods of treating acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are provided, as are compositions and combinations suitable for use in said methods.
    Type: Application
    Filed: June 18, 2018
    Publication date: April 11, 2019
    Inventors: Hans de Haard, Nicolas Leupin, Adrian Ochsenbein, Carsten Riether, Luc Van Rompaey